Corporate Profile for Matrix Pharmaceutical, Inc., dated July 21, 2000.Business Editors --(BUSINESS WIRE) The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services.
Published Date: July 21, 2000
Company Name: Matrix Pharmaceutical, Inc.
Address: 34700 Campus Drive
Fremont, CA 94555
Main Telephone
Number: 510/742-9900
Internet Home
Page Address
(URL) www.matx.com
Chief Executive
Officer: Michael D. Casey
Chief Financial
Officer: David Ludvigson
Investor Relations
Contact: David Ludvigson
Business number: 510/742-9900
E-mail address: Investor_Relations@matx.com
Industry: BioPharmaceutical
Trading Symbol/
Exchange: matx
Market Makers: Banc of America Securities, LLC, Davenport & Co.,
Grunthal & Co., Inc., Herzog Heine, Geduld, Inc.,
Knight Securities, LP, Warburg Dillon Read, Sherwood
Securities Corp., Schwap Capital Markets, Spear
Leeds & Kellogg, Fleet Trading,
Prodential Securities
Company description: Matrix Pharmaceutical, Inc. is developing drug product candidates for cancer based on its internal research and development capabilities and through in-licensing of product candidates from other pharmaceutical companies. Matrix is a leader in the formulation and development of product candidates that are designed to improve the delivery of cancer drugs for more effective treatment of solid tumors. Two product candidates that utilize the Company's aqueous-based protein gel system are currently being evaluated in human clinical trials. These are IntraDose(R) (cisplatin/epinephrine) Injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. Gel and MPI MPI - Message Passing Interface 5020 Radiopotentiator. In-licensed in 1998, Matrix is also developing FMdC as an intravenously administered therapeutic in non-small cell lung cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. , colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. , hematologic hematological, hematologic pertaining to or emanating from blood cells. hematological tests total and differential white cell counts, hematocrit estimation, erythrocyte count. and other cancers. IntraDose incorporates cisplatin cisplatin /cis·plat·in/ (sis´plat-in) DDP; a platinum coordination complex capable of producing inter- and intrastrand DNA crosslinks; used as an antineoplastic. cis·plat·in n. , the widely used anti-cancer drug, and epinephrine, into a collagen gel matrix. IntraDose has completed two pivotal Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA trials in recurrent or refractory head and neck cancer. The Company expects to file an NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any by the end of 2000. In 1999, Matrix had no revenues, costs and expenses of $23.5 million and recorded a loss of $0.94 per share. Including a recent private financing, the Company will have more than $60 million of cash as of mid-2000. Matrix employs approximately 100 people. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion